EICHORCondition: Advanced Solid Tumors · Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy, or without available standard or curative therapy.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The Affiliated Hospital of USTC | Hefei, Anhui, China | — |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | — |
| Henan Cancer Hospital | Zhenzhou, Henan, China | — |
| The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University | Changsha, Hunan, China | — |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | — |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06076291